279 related articles for article (PubMed ID: 30518036)
21. Pharmacological telomerase inhibition can sensitize drug-resistant and drug-sensitive cells to chemotherapeutic treatment.
Ward RJ; Autexier C
Mol Pharmacol; 2005 Sep; 68(3):779-86. PubMed ID: 15939802
[TBL] [Abstract][Full Text] [Related]
22. Genetic and Epigenetic Modulation of Drug Resistance in Cancer: Challenges and Opportunities.
Shah K; Rawal RM
Curr Drug Metab; 2019; 20(14):1114-1131. PubMed ID: 31902353
[TBL] [Abstract][Full Text] [Related]
23. Epigenetic treatment combinations to effectively target cisplatin-resistant germ cell tumors: past, present, and future considerations.
Oing C; Skowron MA; Bokemeyer C; Nettersheim D
Andrology; 2019 Jul; 7(4):487-497. PubMed ID: 30924611
[TBL] [Abstract][Full Text] [Related]
24. Research Advances in the Use of Histone Deacetylase Inhibitors for Epigenetic Targeting of Cancer.
Bai Y; Ahmad D; Wang T; Cui G; Li W
Curr Top Med Chem; 2019; 19(12):995-1004. PubMed ID: 30686256
[TBL] [Abstract][Full Text] [Related]
25. Non-Hodgkin's B-cell lymphoma: advances in molecular strategies targeting drug resistance.
Maxwell SA; Mousavi-Fard S
Exp Biol Med (Maywood); 2013 Sep; 238(9):971-90. PubMed ID: 23986223
[TBL] [Abstract][Full Text] [Related]
26. The epigenetics of ovarian cancer drug resistance and resensitization.
Balch C; Huang TH; Brown R; Nephew KP
Am J Obstet Gynecol; 2004 Nov; 191(5):1552-72. PubMed ID: 15547525
[TBL] [Abstract][Full Text] [Related]
27. Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer.
Dueñas-Gonzalez A; Coronel J; Cetina L; González-Fierro A; Chavez-Blanco A; Taja-Chayeb L
Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1433-44. PubMed ID: 25154405
[TBL] [Abstract][Full Text] [Related]
28. The Goal of Cancer Treatment.
Balis FM
Oncologist; 1998; 3(4):V. PubMed ID: 10388118
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic reprogramming and potential application of epigenetic-modifying drugs in acquired chemotherapeutic resistance.
Ponnusamy L; Mahalingaiah PKS; Singh KP
Adv Clin Chem; 2020; 94():219-259. PubMed ID: 31952572
[TBL] [Abstract][Full Text] [Related]
30. Epigenetics and Lymphoma: Can We Use Epigenetics to Prime or Reset Chemoresistant Lymphoma Programs?
Lue JK; Amengual JE; O'Connor OA
Curr Oncol Rep; 2015 Sep; 17(9):40. PubMed ID: 26141799
[TBL] [Abstract][Full Text] [Related]
31. Enhancing the Anticancer Efficacy of Immunotherapy through Combination with Histone Modification Inhibitors.
Sun W; Lv S; Li H; Cui W; Wang L
Genes (Basel); 2018 Dec; 9(12):. PubMed ID: 30558227
[TBL] [Abstract][Full Text] [Related]
32. New anti-cancer strategies: epigenetic therapies and biomarkers.
Balch C; Montgomery JS; Paik HI; Kim S; Kim S; Huang TH; Nephew KP
Front Biosci; 2005 May; 10():1897-931. PubMed ID: 15769674
[TBL] [Abstract][Full Text] [Related]
33. Epigenetic alternations and cancer chemotherapy response.
Lv JF; Hu L; Zhuo W; Zhang CM; Zhou HH; Fan L
Cancer Chemother Pharmacol; 2016 Apr; 77(4):673-84. PubMed ID: 26707728
[TBL] [Abstract][Full Text] [Related]
34. Clinical reversal of drug resistance.
Goldstein LJ
Curr Probl Cancer; 1995; 19(2):65-124. PubMed ID: 7600845
[TBL] [Abstract][Full Text] [Related]
35. Epigenetic reprogramming in breast cancer: from new targets to new therapies.
Katz TA; Huang Y; Davidson NE; Jankowitz RC
Ann Med; 2014 Sep; 46(6):397-408. PubMed ID: 25058177
[TBL] [Abstract][Full Text] [Related]
36. Are ovarian cancer stem cells the target for innovative immunotherapy?
Wang L; Xu T; Cui M
Onco Targets Ther; 2018; 11():2615-2626. PubMed ID: 29780254
[TBL] [Abstract][Full Text] [Related]
37. Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells.
Trivedi R; Mishra DP
Front Oncol; 2015; 5():69. PubMed ID: 25883904
[TBL] [Abstract][Full Text] [Related]
38. Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors.
Dalvi MP; Wang L; Zhong R; Kollipara RK; Park H; Bayo J; Yenerall P; Zhou Y; Timmons BC; Rodriguez-Canales J; Behrens C; Mino B; Villalobos P; Parra ER; Suraokar M; Pataer A; Swisher SG; Kalhor N; Bhanu NV; Garcia BA; Heymach JV; Coombes K; Xie Y; Girard L; Gazdar AF; Kittler R; Wistuba II; Minna JD; Martinez ED
Cell Rep; 2017 May; 19(8):1669-1684. PubMed ID: 28538184
[TBL] [Abstract][Full Text] [Related]
39. Multiple genetic and epigenetic interacting mechanisms contribute to clonally selection of drug-resistant tumors: current views and new therapeutic prospective.
Roberti A; La Sala D; Cinti C
J Cell Physiol; 2006 Jun; 207(3):571-81. PubMed ID: 16250021
[TBL] [Abstract][Full Text] [Related]
40. [Application of epigenetics to cancer diagnosis and therapy].
Ushijima T; Kikuyama M; Takeshima H
Nihon Geka Gakkai Zasshi; 2012 Mar; 113(2):191-6. PubMed ID: 22582579
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
